Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 6:16 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 11,569 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: CHRONIC DISEASE Clear all
Recruiting Phase 1Phase 2 Interventional

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

NCT04329728
View directory record Official record
Conditions
Lymphoid Malignancies
Interventions
AVM0703
Drug
Lead sponsor
AVM Biotechnology Inc
Industry
Eligibility
12 Years to 95 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
11
States / cities
Duarte, California • Los Angeles, California • Whittier, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Nov 2, 2026, 6:16 PM EST
Completed Phase 2 Interventional

Efficacy and Safety of Ramelteon in Subjects With Mild to Moderate Alzheimer's Disease

NCT00325728
View directory record Official record
Conditions
Chronic Insomnia
Interventions
Ramelteon, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
55 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
72
States / cities
Alabaster, Alabama • Huntsville, Alabama • Phoenix, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2017 · Synced Nov 2, 2026, 6:16 PM EST
Completed Phase 3 Interventional Results available

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy

NCT02607800
View directory record Official record
Conditions
Hepatitis C
Interventions
SOF/VEL/VOX, SOF/VEL
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
943 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
47
States / cities
Long Beach, California • Los Angeles, California • Palo Alto, California + 44 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Nov 2, 2026, 6:16 PM EST
Not listed No phase listed Observational

Procurement of Blood Samples for a Biomedical Research Program on T Cell Functional Response to Chronic HBV Infection

NCT02017587
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
Not listed
Lead sponsor
Vaccine and Gene Therapy Institute, Florida
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 26, 2015 · Synced Nov 2, 2026, 6:16 PM EST
Completed Not applicable Interventional

Narrative Intervention for Long COVID-19 (NICO)

NCT06091293
View directory record Official record
Conditions
Long COVID, Long Covid19
Interventions
Narrative Intervention for Long COVID-19 (NICO)
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Nov 2, 2026, 6:16 PM EST
Completed No phase listed Observational

Caregiver Support in the Coping of Patients Who Are Undergoing a Donor Bone Marrow Transplant

NCT00281814
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Psychosocial Effects of Cancer and Its Treatment
Interventions
psychosocial assessment and care
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 26, 2018 · Synced Nov 2, 2026, 6:16 PM EST
Not yet recruiting Not applicable Interventional

Combined Aphasia and Robot-Assisted Arm Treatment for Chronic Stroke Survivors

NCT07000019
View directory record Official record
Conditions
Stroke, Aphasia Following Cerebral Infarction, Hemiparesis After Stroke
Interventions
CARAT: combined aphasia and robot-assisted arm therapy, Robot-assisted arm therapy
Behavioral
Lead sponsor
New York Medical College
Other
Eligibility
18 Years to 90 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Valhalla, New York
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Nov 2, 2026, 6:16 PM EST
Completed Not applicable Interventional

Best Endovascular vs. Best Surgical Therapy in Patients With Critical Limb Ischemia

NCT02060630
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
Open surgical revascularization, Endovascular revascularization
Procedure · Device
Lead sponsor
Carelon Research
Other
Eligibility
18 Years and older
Enrollment
1,843 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
144
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 102 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Nov 2, 2026, 6:16 PM EST
Completed Phase 2 Interventional Results available

Broccoli Sprout Extracts Trial to See if NRF2 is Enhanced by Sulforaphane Treatment in Patients With COPD

NCT01335971
View directory record Official record
Conditions
COPD
Interventions
Sulforaphane 25, Sulforaphane 150, Placebo
Drug · Dietary Supplement · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
3
States / cities
Baltimore, Maryland • Buffalo, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 19, 2017 · Synced Nov 2, 2026, 6:16 PM EST
Completed Phase 1Phase 2 Interventional Results available

Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT01892371
View directory record Official record
Conditions
FLT3 Gene Mutation Negative, FLT3 Internal Tandem Duplication Positive, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome
Interventions
Azacitidine, Cytarabine, Quizartinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 2, 2026, 6:16 PM EST
Completed Phase 1 Interventional

Open Label Study to Assess the Effect of Patient Use and Robustness of Tiotropium 18ug Inhalation Powder, Hard Capsule,Zephir Inhaler Device

NCT06254664
View directory record Official record
Conditions
COPD
Interventions
Tiotropium 18 µg inhalation powder, hard capsule, Zephir inhaler
Drug · Device
Lead sponsor
Xiromed LLC
Industry
Eligibility
40 Years to 75 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
8
States / cities
Fort Myers, Florida • Kissimmee, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2024 · Synced Nov 2, 2026, 6:16 PM EST
Withdrawn No phase listed Observational

Protocol to Obtain Blood for Discovery of Novel Biomarkers and Potential Therapeutic Targets in Chronic Lymphocytic Leukemia

NCT01069432
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
No Intervention
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 19, 2018 · Synced Nov 2, 2026, 6:16 PM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease

NCT02540993
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Finerenone (BAY94-8862), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
5,734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
176
States / cities
Birmingham, Alabama • Fort Payne, Alabama • Huntsville, Alabama + 125 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Nov 2, 2026, 6:16 PM EST
Completed Phase 3 Interventional Results available

Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant

NCT02032875
View directory record Official record
Conditions
Hepatitis C
Interventions
Daclatasvir, Sofosbuvir, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
Miami, Florida • Ann Arbor, Michigan • Houston, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Nov 2, 2026, 6:16 PM EST
Completed Phase 3 Interventional Results available

16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis

NCT01649375
View directory record Official record
Conditions
Anklyosing Spondylitis
Interventions
Secukinumab (75 mg), Placebo, Secukinumab (150 mg)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
10
States / cities
Mesa, Arizona • Upland, California • Edina, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Nov 2, 2026, 6:16 PM EST
Recruiting No phase listed Observational

MRI Biomarkers in as Predictor of Clinical Endpoints in Pediatric Autoimmune Liver Disease

NCT03178630
View directory record Official record
Conditions
Autoimmune Liver Disease, Autoimmune Hepatitis, Primary Sclerosing Cholangitis
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 23 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2031
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Nov 2, 2026, 6:16 PM EST
Not listed Phase 3 Interventional

Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia

NCT00020865
View directory record Official record
Conditions
Fever, Sweats, and Hot Flashes, Infection, Leukemia, Lymphoma, Neutropenia, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cefepime hydrochloride, levofloxacin
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Nov 2, 2026, 6:16 PM EST
Recruiting Not applicable Interventional

Measuring Brain Complexity to Detect and Predict Recovery of Consciousness in the ICU

NCT06568536
View directory record Official record
Conditions
Consciousness Disorders
Interventions
Repeated behavioral assessments, functional electroencephalography and brain imagery, TMS-EEG
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Nov 2, 2026, 6:16 PM EST
Terminated No phase listed Observational Accepts healthy volunteers

REduction of Contrast Via DyeVert Used in CTO Procedures

NCT03118544
View directory record Official record
Conditions
Chronic Total Occlusion of Coronary Artery
Interventions
DyeVert System
Device
Lead sponsor
Minneapolis Heart Institute Foundation
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
3
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Nov 2, 2026, 6:16 PM EST
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease

NCT06154837
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK3862995B, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
10
States / cities
Yuma, Arizona • Hialeah, Florida • Orange City, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Nov 2, 2026, 6:16 PM EST
Completed Phase 3 Interventional Results available

Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia

NCT01741545
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
Pegylated-Interferon-lambda, Ribavirin, Daclatasvir
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Male only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
4
States / cities
Palo Alto, California • Chicago, Illinois • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Nov 2, 2026, 6:16 PM EST
Completed Phase 2 Interventional Results available

FCR and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia (CLL)

NCT00448019
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Fludarabine, Cyclophosphamide, Rituximab, Bevacizumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2015 · Synced Nov 2, 2026, 6:16 PM EST
Completed Phase 3 Interventional

Evaluation of Manufacturing Lot of StaphVAX

NCT00211900
View directory record Official record
Conditions
Staphylococcal Infections, Chronic Kidney Failure
Interventions
S. aureus Type 5 & 8 Capsular Polysaccharide Vaccine
Biological
Lead sponsor
Nabi Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Madison, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 4, 2008 · Synced Nov 2, 2026, 6:16 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of IFN-γ on Innate Immune Cells

NCT02609932
View directory record Official record
Conditions
Chronic Granulomatous Disease
Interventions
Administration of drug (Interferon-gamma 1-b) subcutaneously
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Nov 2, 2026, 6:16 PM EST